<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03992404</url>
  </required_header>
  <id_info>
    <org_study_id>M602011014</org_study_id>
    <secondary_id>2018-001639-35</secondary_id>
    <nct_id>NCT03992404</nct_id>
  </id_info>
  <brief_title>Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury</brief_title>
  <acronym>PATTERN</acronym>
  <official_title>Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a single treatment with administration of
      400 Units NT 201 (botulinum toxin) is superior to placebo (no medicine) for the treatment of
      lower limb spasticity caused by stroke or traumatic brain injury (Main Period). Participants
      will be assigned to the treatment groups by chance and neither the participants nor the
      research staff who interact with them will know the allocation.

      The following 4 to 5 treatment cycles will investigate the safety and tolerability of
      treatment with NT 201 (botulinum toxin) when administered in doses between 400 and 800 Units
      (Open Label Extension Period). All participants will receive the treatment and the dose will
      depend on whether only lower limb spasticity or combined upper and lower limb spasticity are
      treated.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 16, 2019</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in derived Modified Ashworth Scale-Bohannon (MAS) ankle score (knee extended) at weeks 4 to 6</measure>
    <time_frame>Baseline to week 4-6</time_frame>
    <description>The MAS is a 6-grade scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Co-Primary: Global Impression of Change Scale (GICS) assessed by physician at Week 4 to 6</measure>
    <time_frame>Week 4-6</time_frame>
    <description>The GICS s a 9-grade scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of treatment emergent adverse events [TEAEs] in the Main Period</measure>
    <time_frame>Baseline to week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Study Baseline in Goal Attainment Scale [GAS] at Week 6</measure>
    <time_frame>Baseline to week 6</time_frame>
    <description>The GAS is a 6-grade scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Impression of Change Scale (GICS) assessed by the study subject at Week 4 to 6</measure>
    <time_frame>Week 4-6</time_frame>
    <description>The GICS s a 9-grade scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Impression of Change Scale (GICS) assessed by the caregiver at Week 4 to 6</measure>
    <time_frame>Week 4-6</time_frame>
    <description>The GICS s a 9-grade scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>NT 201 (IncobotulinumtoxinA, Xeomin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Main Period (1 treatment cycle): subjects to receive intramuscular injection of NT 201 (400 units) into muscles of the lower limb.
Open Label Extension Period (4-5 treatment cycles): subjects to receive intramuscular injection of NT 201 (up to 800 units) into muscles of the lower limb and upper limb, if indicated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Main Period (1 treatment cycle): subjects to receive intramuscular placebo injection into muscles of the lower limb.
Open Label Extension Period (4-5 treatment cycles): subjects to receive intramuscular injection of NT 201 (up to 800 units) into muscles of the lower limb and upper limb, if indicated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NT 201</intervention_name>
    <description>Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).</description>
    <arm_group_label>NT 201 (IncobotulinumtoxinA, Xeomin)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>IncobotulinumtoxinA</other_name>
    <other_name>Incobotulinumtoxin A</other_name>
    <other_name>Xeomin</other_name>
    <other_name>Botulinum toxin type A (150 kiloDalton), free from complexing proteins</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female or male subject ≥ 18 years and ≤ 85 years at screening

          -  Diagnosis of lower limb spasticity with or without upper limb spasticity of the same
             body side caused by stroke or traumatic brain injury

          -  Disabling ankle flexor spasticity presenting as pes equinus or pes equinovarus

          -  Modified Ashworth Scale-Bohannon [MAS] score of 2 or 3 points in the ankle plantar
             flexor of the target lower limb (supine position, knee extended)

          -  Minimum passive range of motion in ankle of the target lower limb (supine position,
             knee extended): 10°dorsiflexion and 20°plantarflexion

          -  At least 4 months since last botulinum neurotoxin [BoNT] injection for treatment of
             spasticity or any other condition

          -  For subjects receiving anticoagulation therapy, the investigator confirms and
             documents that the subject has an:

          -  Activated partial thromboplastin time [aPTT] ≤ 80 seconds (subjects on dabigatran or
             other direct thrombin inhibitors) or

          -  International normalized ratio [INR] value of ≤ 2.5 (subjects on coumarins or other
             anticoagulants monitored by INR)

        Exclusion Criteria:

          -  Generalized disorders of muscle activity (e.g. myasthenia gravis, Lambert Eaton
             syndrome, amyotrophic lateral sclerosis) or any other significant peripheral
             neuromuscular dysfunction which might interfere with the study

          -  Bilateral lower limb paresis/paralysis/spasticity or tetraparesis/paralysis/spasticity

          -  Body weight &lt; 50 kg

          -  Severe atrophy of the target limb muscles

          -  Previous, ongoing or planned treatments of spasticity with intrathecal baclofen

          -  Previous, ongoing, or planned treatments of spasticity in the target lower limb with
             any of the following procedures: Surgical Intervention; Alcohol or phenol block;
             Muscle afferent block

          -  Physiotherapy or use of orthoses or splints at the target limb initiated less than 4
             weeks before screening or expected to change during the double blind phase of the
             study

          -  Current or planned treatment with parenterally administered drugs that interfere with
             neuromuscular transmission (e.g. intrathecal baclofen, tubocurarine type muscle
             relaxants used in anesthesia), or local anesthetics in the treated region within 2
             weeks prior to screening

          -  Infection or inflammation at the injection sites

          -  Subjects with presence or history of aspiration pneumonia, recurrent lower respiratory
             tract infections, or compromised respiratory function as per investigator's clinical
             judgment

          -  Pregnancy (as verified by a positive pregnancy test) or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merz Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>Merz Pharmaceuticals GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New England institute for clinical research; Merz Investigational Site #0010441</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard A. Rusk Rehabilitation Center; Merz investigational site #0010283</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai, neurology department, Merz Investigational Site #0010191</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center, Department of Rehabilitation Medicine; Merz Investigational Site #0010440</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center, Physical Medicine &amp; Rehabiliation, Merz Investigational Site #0010211</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin,Department of PM&amp;R, Merz Investigational Site #0010237</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George Hospital, Department of Rehabilitation Medicine, Merz Investigational Site #0610004</name>
      <address>
        <city>Kogarah</city>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital, Department of Rehabilitation Medicine; Merz Investigational Site #0610002</name>
      <address>
        <city>Parkville</city>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Bruxelles, Physical Medicine &amp; Rehabilitation Department, Merz Investigational Site #0320013</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Mont Godinne, Physical Medicine &amp; Rehabilitation Department; Merz Investigational Site #0320008</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology and Physiotherapy Skopalikova, Merz Investigational Site #4200049</name>
      <address>
        <city>Brno</city>
        <zip>61500</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Kralovske Vinohrady, Neurology Department, Merz Investigational Site #4200050</name>
      <address>
        <city>Prague</city>
        <zip>10034</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raymond Poincaré University Hospital, Service de MPR Pôle Handicap-Rééducation; Merz Investigational Site #0330018</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Readaptation Clemenceau, Physical Medicine / Rehabilitation Medecine, Merz Investigational site # 0330063</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen, Neurologie, Merz Investigational Site #0490191</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heinrich Heine University Duesseldorf, Department of Neurology; Merz Investigational Site #0490071</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CBBM, Institut für Neurogenetik, Haus 66; Merz Investigational Site #0490332</name>
      <address>
        <city>Lübeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DKD HELIOS Medical Center, Fachbereich Neurologie, Merz Investigational Site #0490081</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik und Poliklinik des Universitätsklinikums Würzburg, Merz Investigational Site #0490302</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Ospedali Riuniti Di Foggia; Merz Investigational Site #0390018</name>
      <address>
        <city>Foggia</city>
        <zip>71122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore della Carita, Dipartimento di Medicina fisica e Riabilitativa, Merz Investigational Site #0390017</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOUI -Ospedale Borgo Roma, U.O.C Neuroriabilitazione, Merz Investigational Site #0390014</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczna Praktyka Lekarska Dr. n. med Stanisław Ochudło, Merz Investigational Site #0480077</name>
      <address>
        <city>Katowice</city>
        <zip>40-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczne Gabinety Sp z o.o., Merz Investigational Site #0480059</name>
      <address>
        <city>Krakow</city>
        <zip>30-539</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroKlinika Gabinet Lekarski Prof Andrzej Bogucki, Merz Investigational Site #0480101</name>
      <address>
        <city>Lodz</city>
        <zip>90-460</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne MEDICOS S.A., Merz Investigational Site #0480096</name>
      <address>
        <city>Lublin</city>
        <zip>20-582</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;AMED&quot; Centrum Medyczne, Merz Investigational Site #0480100</name>
      <address>
        <city>Warsaw</city>
        <zip>01-518</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Projekt Samodzielni Sp z o.o., Merz Investigational Site #0480099</name>
      <address>
        <city>Warsaw</city>
        <zip>02-366</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Psychiatrii i Neurologii, II Klinika Neurologiczna, Merz Investigational Site #0480023</name>
      <address>
        <city>Warsaw</city>
        <zip>02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mazowiecki Szpital Brodnowski, Merz investigational site #0480064</name>
      <address>
        <city>Warsaw</city>
        <zip>03-242</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Krasnoyarsk State Medical University n.a. Professor V.F. Voino-Yasenetskiy of Ministry Healthcare of Russian Federation&quot;, Merz Investigational Site #0070306</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Autonomous Institution of Healthcare of Moscow City &quot;Moscow Scientific and Practical Centre of Medical Rehabilitation, Regenerative and Sports Medicine of Moscow City Healthcare Department&quot;, Merz Investigational Site #0070011</name>
      <address>
        <city>Moscow</city>
        <zip>105005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Autonomous Institution &quot;National Medical Research Centre &quot;Treatment and Rehabilitation&quot; of the Ministry of Health of the Russian Federation, Neurology department, Merz Investigational Site # 0070305</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution &quot;National Medical Research Centre of Psychiatry and Neurology n.a. V.M. Bekhterev&quot; of the Ministry of Healthcare of the Russian Federation, Merz Investigational Site #0070009</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195119</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz, Merz Investigational Site #0340007</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Mútua de Terrassa, Merz Investigational Site #0340003</name>
      <address>
        <city>Terrassa</city>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois - Neurorehabilitation and Physical Medicine, Merz Investigational Site #0410013</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust; Merz Investigational Site 0440023</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Foundation Trust Hospital, Department of Neurology, Merz Investigational Site #0440047</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Walton Centre NHS Foundation Trust; Neuroscience Research Centre; Merz Investigational site #0440004</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital for Neurology and Neurosurgery - UCLH; Merz Investigational Site #0440033</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

